NASDAQ$RGEN
Repligen Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Repligen's Q3 2021 performance was strong, marked by record revenue and significant organic growth, driven by base business and COVID-related sales.
Repligen reported record revenue of $178.2 million for Q3 2021, representing an 89% year-over-year increase and 77% organic growth. The company's base business grew by 49%, with COVID programs accounting for approximately 27% of revenue. The acquisition of Avitide Inc. was completed, strengthening the Proteins franchise. Full-year revenue guidance was raised to $655-$665 million.
- Revenue reached a record $178.2 million, with an 89% year-over-year increase and 77% organic growth.
- Base business revenue increased by 49% year-over-year, accounting for 67% of total revenue.
- COVID-related sales grew 247% year-over-year and accounted for 27% of revenue.
- GAAP operating margin was 25.4%, an increase of 310 bps, and adjusted operating margin was 32%, an increase of 340 bps.
Headline financials
Revenue & EPS history
Repligen · Revenue · Quarterly
$178M
Revenue by segment
Repligen · $141M total across 2 segments · Q3 2023
- Product Revenue$141M—100.0%
- Royalty and Other$36—0.0%
Forward guidance
Repligen updated its financial guidance for fiscal year 2021, expecting total revenue in the range of $655-$665 million, reflecting overall revenue growth of 79%-82% and organic growth of 65%-68%.
Tailwinds
- Total revenue is expected to be in the range of $655-$665 million, an increase from the previous guidance of $625-$645 million.
- Overall revenue growth is projected at 79%-82% and 77%-80% at constant currency.
- Organic growth is expected to be in the range of 65%-68%, an increase from the previous guidance of 57%-62%.
- GAAP income from operations is expected to be in the range of $165-$169 million, an increase from the previous guidance of $156-$161 million.
- Adjusted (non-GAAP) income from operations is expected to be in the range of $204-$208 million, an increase from the previous guidance of $192-$197 million.
Headwinds
- Guidance excludes the impact of potential additional acquisitions.
- Guidance excludes future fluctuations in foreign currency exchange rates.
- Acquisition and integration expenses are estimated at $14.7 million.
- Expected inventory step-up charges of $1.9 million related to acquisitions.
- Estimated intangible amortization expense of $22.1 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+2.6%
Avg return
Earnings day
+3.4%
Avg return
5 days after
+4.4%
Avg return
30 days after
59%
36 / 61 earnings
Positive
+22.1%
Q3 2018
Best reaction
-23.0%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | -7.8% | -2.7% | |
| Q4 2025 | +1.4% | -4.9% | -15.5% | |
| Q3 2025 | -5.9% | -7.5% | +6.3% | |
| Q1 2025 | -2.9% | -1.5% | -14.8% | |
| Q4 2024 | +7.9% | +7.1% | -7.1% | |
| Q3 2024 | +7.9% | -10.6% | +11.8% | |
| Q2 2024 | +21.3% | +17.2% | +9.2% | |
| Q1 2024 | +1.3% | +2.3% | -9.2% | |
| Q4 2023 | -3.2% | -4.0% | -0.9% | |
| Q3 2023 | +15.1% | +31.7% | +37.7% | |
| Q2 2023 | +1.1% | +2.5% | +5.2% | |
| Q1 2023 | +6.4% | +4.3% | +8.8% | |
| Q4 2022 | +3.2% | -2.7% | -10.0% | |
| Q3 2022 | -6.0% | -4.5% | +3.1% | |
| Q2 2022 | +13.1% | +15.9% | +0.6% | |
| Q1 2022 | +7.8% | +11.4% | +19.3% | |
| Q4 2021 | -1.8% | -1.4% | +4.0% | |
| Q3 2021 | +7.2% | +11.7% | +5.5% | |
| Q2 2021 | +14.2% | +19.3% | +32.4% | |
| Q1 2021 | -6.4% | -9.8% | -15.6% | |
| Q4 2020 | +0.3% | +7.4% | -11.1% | |
| Q3 2020 | +8.1% | +0.0% | +0.8% | |
| Q2 2020 | +8.7% | +12.8% | +8.2% | |
| Q1 2020 | +6.7% | +11.9% | +5.0% | |
| Q4 2019 | -10.1% | -22.2% | -18.7% | |
| Q3 2019 | +9.9% | +6.1% | +15.1% | |
| Q2 2019 | -4.0% | -3.2% | -1.7% | |
| Q1 2019 | +2.5% | -0.2% | +11.5% | |
| Q4 2018 | -0.2% | +1.0% | -0.2% | |
| Q3 2018 | +22.1% | +25.2% | +19.3% | |
| Q2 2018 | -1.0% | +2.0% | +14.2% | |
| Q1 2018 | +5.1% | +10.2% | +14.9% | |
| Q4 2017 | +9.2% | +9.5% | +6.2% | |
| Q3 2017 | -7.1% | -13.0% | -4.9% | |
| Q2 2017 | +1.3% | +4.4% | +6.1% | |
| Q1 2017 | +5.2% | +6.3% | +11.7% | |
| Q4 2016 | +6.3% | +6.4% | +13.6% | |
| Q3 2016 | -4.1% | -1.1% | +10.0% | |
| Q2 2016 | -0.6% | -1.1% | +3.9% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | -23.0% | — | — | |
| Q2 2015 | -0.2% | — | — | |
| Q1 2015 | +16.9% | — | — | |
| Q4 2014 | +14.9% | — | — | |
| Q3 2014 | -6.6% | — | — | |
| Q2 2014 | -3.6% | — | — | |
| Q1 2014 | +5.0% | — | — | |
| Q4 2013 | -8.8% | — | — | |
| Q3 2013 | +8.8% | — | — | |
| Q2 2013 | -0.1% | — | — | |
| Q1 2013 | +2.9% | — | — | |
| Q3 2010 | -5.0% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2012 | +10.2% | — | — | |
| Q2 2012 | -0.4% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q1 2011 | -0.9% | — | — | |
| Q4 2011 | -0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro